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in their cohort study, proposed the role of proton pump inhibitors (PPI) as a risk factor of cholangitis, especially during the period 
of their use. This observational result could include unrecog- nized confounders, one of which to consider being the overlap be- tween 
Helicobacter pylori infection (Hp-I) and the conditions treated using a PPI; dyspepsia, peptic ulcer disease and, at least in some pop- 
ulations, gastro-oesophageal reflux disease—Barrett’s oesophagus— oesophageal cancer sequence are associated with Hp-I and represent the 
most frequent indications for PPI prescription.
2 
Moreover Hp-I is involved in PPI-related disorders discussed by the authors.
1-3  
The impact of Hp-I with biliary tree diseases has been described. Bile stasis has primarily been connected with hepatobiliary Hp con- 
tamination, thus leading to a threefold risk of chronic lithiasis and cholecystitis, triggered by a perpetual inflammation of the gallblad- der.
4,5 
In this respect, our data indicated Hp presence in gallbladder tissue in 19.33% of patients who were submitted to cholecystec- tomy due to 
lithiasis,
6 
while chronic biliary Hp-I has been identified in 75% of patients with gallbladder cancer.
7  
The proposed routes of contamination, although unproved, in- clude ascending migration through the sphincter of Oddi and hae- matogenous 
spread to the liver and then excretion into bile. In this respect, the potential influx of activated monocytes infected with Hp (due to defective 
autophagy) from the circulation into the gall- bladder might relate to gallbladder-related pathologies (“Trojan horse” pathway); biliary 
excretion of Hp invaded macrophages might trigger proinflammatory cytokine release, oxidative stress and inflammation, thus promoting 
gallstone formation and its  
complications (cholecystitis/cholangitis/pancreatitis). Additionally, biliary Hp-I could provoke an imbalance of apoptotic cellular pro- cesses 
and contribute to biliary carcinogenesis. In vitro data support this, indicating that Hp promotes cell proliferation and suppresses apoptosis of 
human intrahepatic biliary epithelial cells by increasing reactive oxygen species release.
8 
Finally, the authors suggested as a possible 
pathogenetic mechanism of PPI-related cholangitis, the imbalance between the normal small intestine microbiota and the bacterial 
overgrowth due to gastric acid suppression.
1 
Nevertheless, Hp-I seems to cause more significant alterations in gut microbiota than PPI use, 
thus contributing to biofilm formation.
9  
Hp-I has also been associated with a plethora of extragastric conditions, such as cardiovascular and neurodegenerative diseases, glaucoma, 
gastrointestinal tract oncogenesis, non-alcoholic fatty liver disease and hepatic encephalopathy.
10 
Therefore, it seems rea- sonable to consider 
adjusting for the presence of Hp-I as a potential cofounder in PPI-related disorders, as it is perhaps potentially rele- vant to a wide range of 
conditions necessitating their use.  
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